Stock APLI APPILI THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Appili Therapeutics Inc.

Equities

APLI

CA03783R1073

Market Closed - Toronto S.E.
Other stock markets
 03:31:48 2024-05-01 pm EDT 		5-day change 1st Jan Change
0.035 CAD 0.00% Intraday chart for Appili Therapeutics Inc. -12.50% 0.00%
Apr. 26 Appili Therapeutics Inc. announced that it has received CAD 0.3 million in funding CI
Apr. 02 Appili Therapeutics To be Acquired by Aditxt, Inc. MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Appili Therapeutics Inc. announced that it has received CAD 0.3 million in funding
CI
Appili Therapeutics Signs Definitive Agreement to be acquired by Aditxt, Inc.
AQ
Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense
AQ
Appili Therapeutics To be Acquired by Aditxt, Inc.
MT
Adivir, Inc. entered into a definitive agreement to acquire Appili Therapeutics Inc. for $6.7 million.
CI
Appili Therapeutics Notes Researchers Publish Manuscript on Prevention and Emergency Response to Tularemia Outbreaks
MT
Researchers Publish Manuscript on the Prevention and Emergency Response to Tularemia Outbreaks
AQ
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2024
AQ
Appili Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
CI
Appili Therapeutics Announces Issuance of Patent for ATI-1701 Biodefense Vaccine Candidate to Protect Against Tularemia and Provides Update on Bridge Loan
AQ
Appili Therapeutics Says Patent Issued For Biodefence Vaccine Candidate ATI-1701, Provides Update on Bridge Loan
MT
Appili Therapeutics Brief: Announcing Issuance of Patent for ATI-1701 Biodefense Vaccine Candidate to Protect Against Tularemia and Providing Update on Bridge Loan
MT
Appili Therapeutics Announces Issuance of Patent for ATI-1701 Biodefense Vaccine Candidate to Protect Against Tularemia and Provides Update on Bridge Loan
BU
Appili Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
CI
Appili Therapeutics Inc. Appoints Prakash Gowd to its Board of Directors
CI
Appili Therapeutics Q2 Net Loss and Comprehensive Loss Narrows Vs a Year Ago
MT
Appili Therapeutics Brief: As of September 30, 2023, Co had cash of $0.4 million, compared to $2.5 million on March 31, 2023.
MT
Appili Therapeutics Brief: Net loss and comprehensive loss of $1.0 million or $0.01 loss per share for the Three months ended September 30, 2023
MT
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2024
BU
Appili Therapeutics Biodefense Vaccine Candidate ATI-1701 is Awarded Additional Funding from the U.S. Air Force Academy
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. APLI Stock
  4. News Appili Therapeutics Inc.